Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor. 2012

Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, People's Republic of China.

A series of new tetrahydroprotoberberine (THPB) derivatives were designed, synthesized, and tested for their binding affinity towards dopamine (D(1) and D(2)) and serotonin (5-HT(1A) and 5-HT(2A)) receptors. Many of the THPB compounds exhibited high binding affinity and activity at the dopamine D(1) receptor, as well as high selectivity for the D(1) receptor over the D(2), 5-HT(1A), and 5-HT(2A) receptors. Among these, compound 19c exhibited a promising D(1) receptor binding affinity (K(i)=2.53nM) and remarkable selectivity versus D(2)R (inhibition=81.87%), 5-HT(1A)R (inhibition=61.70%), and 5-HT(2A)R (inhibition=24.96%). Compared with l-(S)-stepholidine (l-SPD) (D(1)K(i)=6.23nM, D(2)K(i)=56.17nM), compound 19c showed better binding affinity for the D(1) receptor (2.5-fold higher) and excellent D(2)/D(1) selectivity. Functional assays found compounds 18j, 18k, and 19c are pure D(1) receptor antagonists. These results indicate that removing the C10 hydroxy group and introducing a methoxy group at C11 of the pharmacophore of l-SPD can reverse the function of THPB compounds at the D(1) receptor. These results are in accord with molecular docking studies.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001600 Berberine Alkaloids A group of related plant alkaloids that contain the BERBERINE heterocyclic ring structure. Berbines,Alkaloids, Berberine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017447 Receptors, Dopamine D1 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES. Dopamine D1 Receptors,Dopamine-D1 Receptor,D1 Receptors, Dopamine,Dopamine D1 Receptor,Receptor, Dopamine-D1
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell

Related Publications

Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
October 2016, Journal of medicinal chemistry,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
July 2016, Molecules (Basel, Switzerland),
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
January 2021, EXCLI journal,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
November 2023, Bioorganic chemistry,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
April 2020, European journal of medicinal chemistry,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
June 2022, Bioorganic & medicinal chemistry letters,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
July 2022, Bioorganic & medicinal chemistry,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
February 2024, Bioorganic & medicinal chemistry letters,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
May 2010, Bioorganic & medicinal chemistry,
Wangke Qian, and Weijian Lu, and Haifeng Sun, and Zeng Li, and Liyuan Zhu, and Rui Zhao, and Lei Zhang, and Shengbin Zhou, and Yu Zhou, and Hualiang Jiang, and Xuechu Zhen, and Hong Liu
November 2014, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!